Tredje AP fonden Lowers Stake in Charles River Laboratories International, Inc. (NYSE:CRL)

Tredje AP fonden reduced its stake in shares of Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 50.0% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 3,996 shares of the medical research company's stock after selling 3,996 shares during the period. Tredje AP fonden's holdings in Charles River Laboratories International were worth $738,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of CRL. Wellington Management Group LLP lifted its holdings in Charles River Laboratories International by 135,927.9% during the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company's stock valued at $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. State Street Corp grew its stake in Charles River Laboratories International by 2.0% in the 3rd quarter. State Street Corp now owns 2,130,279 shares of the medical research company's stock valued at $419,601,000 after buying an additional 41,421 shares in the last quarter. Allspring Global Investments Holdings LLC raised its holdings in Charles River Laboratories International by 2.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 1,808,002 shares of the medical research company's stock valued at $330,231,000 after acquiring an additional 47,221 shares during the period. Charles Schwab Investment Management Inc. lifted its position in shares of Charles River Laboratories International by 7.3% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 552,975 shares of the medical research company's stock worth $102,079,000 after acquiring an additional 37,753 shares in the last quarter. Finally, JPMorgan Chase & Co. boosted its holdings in shares of Charles River Laboratories International by 21.6% in the third quarter. JPMorgan Chase & Co. now owns 482,745 shares of the medical research company's stock worth $95,086,000 after acquiring an additional 85,759 shares during the period. Hedge funds and other institutional investors own 98.91% of the company's stock.

Remove Ads

Charles River Laboratories International Trading Down 1.6 %

Charles River Laboratories International stock traded down $2.91 during mid-day trading on Wednesday, hitting $174.03. The company's stock had a trading volume of 1,072,178 shares, compared to its average volume of 714,189. The business has a 50 day moving average price of $167.21 and a 200-day moving average price of $184.18. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. Charles River Laboratories International, Inc. has a 12 month low of $150.79 and a 12 month high of $274.77. The stock has a market cap of $8.90 billion, a price-to-earnings ratio of 1,160.19, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last released its earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same quarter in the previous year, the company posted $2.46 EPS. Charles River Laboratories International's revenue for the quarter was down 1.1% on a year-over-year basis. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current year.

Insider Activity

In other news, CEO James C. Foster purchased 6,075 shares of the company's stock in a transaction on Thursday, February 20th. The stock was acquired at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares of the company's stock, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Joseph W. Laplume sold 4,400 shares of the stock in a transaction dated Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the sale, the executive vice president now owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. This represents a 18.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 1.30% of the company's stock.

Analysts Set New Price Targets

A number of brokerages recently issued reports on CRL. Robert W. Baird dropped their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. William Blair lowered shares of Charles River Laboratories International from an "outperform" rating to a "market perform" rating in a research report on Wednesday, January 22nd. JPMorgan Chase & Co. decreased their target price on shares of Charles River Laboratories International from $175.00 to $165.00 and set a "neutral" rating on the stock in a report on Thursday, February 20th. The Goldman Sachs Group cut their price target on shares of Charles River Laboratories International from $220.00 to $190.00 and set a "buy" rating for the company in a report on Thursday, January 23rd. Finally, Barclays decreased their price target on shares of Charles River Laboratories International from $205.00 to $166.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 18th. One analyst has rated the stock with a sell rating, fifteen have given a hold rating and one has assigned a buy rating to the stock. According to data from MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and an average price target of $191.31.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).